This could be concluded by observing faster new bone formation [7,9,11,13,20,64,76], good bone quality postsurgically [3], no inflammation in situ [5,25,26,64], lower immune response [9], no sign of infection [22,23,66], suppression of apoptosis [71], visible neoangiogenesis [5,9], more serum fibronectin and vitronectin absorption [71], increased growth factor production and protein absorption [71] and no cytotoxicity in situ [4,6]. The gene discussed is FN1; the disease is infection.